Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report
Keigo Kobayashi(Osaka Gakuin University), Kenzo Soejima(Keio University), Akifumi Mitsuishi(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Hidenori Takahashi(Osaka International Cancer Institute), Daisuke Arai(Keio University), Atsushi Chiyotani(Saiseikai Utsunomiya hospital), Kaori Sakurai(Keio University), Toshiyuki Tahara(Saiseikai Utsunomiya hospital), Katsunori Masaki(Keio University)
Cited by 7
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
A novel image‐guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation
|Journal of Surgical Oncology|2009|333